Common use of Representative’s Warrant Clause in Contracts

Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the First Closing Date (as defined below) warrants to purchase such number of Ordinary Shares equal to ten percent (10%) of the sum of (i) the Firm Shares, plus (ii) if any, the Option Shares issued at the Closing (the “Representative’s Warrant”). The Representative’s Warrant may be purchased in cash or via cashless exercise, shall be exercisable for a period of five years from the Effective Date (as defined below) of the Registration Statement (as defined below) and will terminate on the fifth anniversary of the Effective Date of the Registration Statement. The exercise price of the Representative’s Warrant is equal to one hundred and ten percent (110%) of the initial public offering price of a Firm Share. The Representative’s Warrant and the Ordinary Shares issuable upon exercise of the Representative’s Warrant will be deemed compensation by FINRA, and therefore will be subject to FINRA Rule 5110. In accordance with FINRA Rule 5110(e)(1), neither the Representative’s Warrant nor any of the Ordinary Shares issued upon exercise of the Representative’s Warrant may be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities by any person, for a period of 180 days beginning on the date of commencement of sales of this Offering pursuant to which the Representative’s Warrant is being issued, subject to certain exceptions permitted by FINRA Rule 5110(e)(2).

Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the (i) First Closing Date (as defined below) Date, warrants to purchase such number of Ordinary Shares equal to ten percent (10%) of the sum of (i) Firm Shares issued on the Firm Shares, plus First Closing Date and (ii) on each Option Closing Date, if anyand as applicable, warrants to purchase such number of Ordinary Shares equal to ten percent (10%) of the Option Shares issued at the such Option Closing Date, if and as applicable (collectively, the “Representative’s WarrantWarrants”). The Representative’s Warrant may be purchased in exercised by the payment of cash or via cashless exercise, shall be exercisable for a period of five years from the Effective Date (as defined below) of the Registration Statement (as defined below) and will terminate on the fifth anniversary of the Effective Date of the Registration Statement. The exercise price of the Representative’s Warrant is equal to one hundred and ten twenty five percent (110125%) of the initial public offering price of a Firm ShareSecurity. The Representative’s Warrant and the Ordinary Shares issuable upon exercise of the Representative’s Warrant will be deemed compensation by FINRAFINRA (as defined below), and therefore will be subject to FINRA Rule 51105110(g)(1). In accordance with FINRA Rule 5110(e)(1), neither the Representative’s Warrant nor any of the Ordinary Shares issued upon exercise of the Representative’s Warrant may be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities by any person, for a period of 180 one hundred and eighty (180) days beginning on the date of commencement of sales of this Offering pursuant to which the Representative’s Warrant is being issuedEffective Date, subject to certain exceptions permitted by as set forth in FINRA Rule 5110(e)(2).

Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the First Closing Date (as defined below) warrants to purchase such number of Ordinary Shares equal to ten percent (10%) percent of the sum of (i) the Firm Shares, plus (ii) if any, the Option Shares issued at the Closing (the “Representative’s Warrant”). The Representative’s Warrant may be purchased in exercised by the payment of cash or via cashless exercise, shall be exercisable for a period of five years from the Effective Date (as defined below) of the Registration Statement (as defined below) and will terminate on the fifth anniversary of the Effective Date of the Registration Statement. The exercise price of the Representative’s Warrant is equal to one hundred and ten percent (110%) percent of the initial public offering price of a Firm Share. The Representative’s Warrant and the Ordinary Shares issuable upon exercise of the Representative’s Warrant will be deemed compensation by FINRA, and therefore will be subject to FINRA Rule 51105110(g)(1). In accordance with FINRA Rule 5110(e)(15110(g)(1), neither the Representative’s Warrant nor any of the Ordinary Shares issued upon exercise of the Representative’s Warrant may be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities by any person, for a period of 180 days beginning on immediately following the date of commencement effectiveness of sales of this Offering the Registration Statement pursuant to which the Representative’s Warrant is being issued, subject to certain exceptions permitted by FINRA Rule 5110(e)(2)exceptions.

Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the First Closing Date (as defined below) warrants to purchase such number of Ordinary Shares equal to ten percent (10%) of the sum of (i) the Firm Shares, plus (ii) if any, the Option Shares issued at the Closing (the “Representative’s Warrant”). The Representative’s Warrant may be purchased in cash or via cashless exercise, shall be exercisable for a period of five years from the Effective Date (as defined below) of the Registration Statement (as defined below) and will terminate on the fifth anniversary of the Effective Date of the Registration Statement. The exercise price of the Representative’s Warrant is equal to one hundred and ten twenty percent (110%) of the price of the initial public offering price of a Firm Share. The Representative’s Warrant and the Ordinary Shares issuable upon exercise of the Representative’s Warrant will be deemed compensation by FINRA, and therefore will be subject to FINRA Rule 51105110(g)(1). In accordance with FINRA Rule 5110(e)(15110(g)(1), neither the Representative’s Warrant nor any of the Ordinary Shares issued upon exercise of the Representative’s Warrant may be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities by any person, for a period of 180 days beginning on immediately following the date of commencement effectiveness of sales of this Offering the Registration Statement pursuant to which the Representative’s Warrant is being issued, subject to certain exceptions permitted by FINRA Rule 5110(e)(2)exceptions.

Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the First Closing Date (as defined below) warrants to purchase such number of Ordinary Shares common shares equal to ten eight percent (10%) of the sum of (i) the Firm Shares, plus (ii) if any, the Option Shares issued at the Closing (the “Representative’s Warrant”). The Representative’s Warrant may be purchased in cash or via cashless exercise, shall be exercisable for a period of five years from the Effective Date (as defined below) of the Registration Statement (as defined below) and will terminate on the fifth anniversary of the Effective Date of the Registration Statement. The exercise price of the Representative’s Warrant is equal to one hundred and ten twenty percent (110%) of the initial price of the public offering price of a Firm Share. The Representative’s Warrant and the Ordinary Shares common shares issuable upon exercise of the Representative’s Warrant will be deemed compensation by FINRA, and therefore will be subject to FINRA Rule 51105110(g)(1). In accordance with FINRA Rule 5110(e)(15110(g)(1), neither the Representative’s Warrant nor any of the Ordinary Shares issued upon exercise of the Representative’s Warrant may be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities by any person, for a period of 180 days beginning on immediately following the date of commencement effectiveness of sales of this Offering the Registration Statement pursuant to which the Representative’s Warrant is being issued, subject to certain exceptions permitted by FINRA Rule 5110(e)(2)exceptions.

Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the (i) First Closing Date Date, warrants to purchase such number of Ordinary Shares equal to ten (10) percent of the Firm Shares issued at such and Closing and (ii) on the Second Closing Date, if and as defined below) applicable, warrants to purchase such number of Ordinary Shares equal to ten percent (10%) of the sum of (i) the Firm Shares, plus (ii) if any, the Option Shares issued at the Closing such Closing, if and as applicable (collectively, the “Representative’s WarrantWarrants”). The Representative’s Warrant may be purchased in exercised by the payment of cash or via cashless exercise, shall be exercisable for a period of five years from the Effective Date (as defined below) of the Registration Statement (as defined below) and will terminate on the fifth anniversary of the Effective Date of the Registration Statement. The exercise price of the Representative’s Warrant is equal to one hundred and ten percent (110%) percent of the initial public offering price of a Firm ShareSecurity. The Representative’s Warrant and the Ordinary Shares issuable upon exercise of the Representative’s Warrant will be deemed compensation by FINRAFINRA (as defined below), and therefore will be subject to FINRA Rule 51105110(g)(1). In accordance with FINRA Rule 5110(e)(1), neither the Representative’s Warrant nor any of the Ordinary Shares issued upon exercise of the Representative’s Warrant may be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities by any person, for a period of 180 days nine (9) months beginning on the date of commencement of sales of this Offering pursuant to which the Representative’s Warrant is being issuedOffering, subject to certain exceptions permitted by as set forth in FINRA Rule 5110(e)(2).

Representative’s Warrant. The Company hereby agrees to issue to the Representative (and/or its designees) on the First Closing Date (as defined below) warrants to purchase such number of Ordinary Shares equal to ten percent (10%) of the sum of (i) the Firm Shares, plus (ii) if any, the Option Shares issued at the Closing (the “Representative’s Warrant”). The Representative’s Warrant may be purchased in cash or via cashless exercise, shall be exercisable for a period of five years from the Effective Date (as defined below) of the Registration Statement (as defined below) and will terminate on the fifth anniversary of the Effective Date of the Registration Statement. The exercise price of the Representative’s Warrant is equal to one hundred and ten fifteen percent (110%) of the price of the initial public offering price of a Firm Share. The Representative’s Warrant and the Ordinary Shares issuable upon exercise of the Representative’s Warrant will be deemed compensation by FINRA, and therefore will be subject to FINRA Rule 51105110(g)(1). In accordance with FINRA Rule 5110(e)(15110(g)(1), neither the Representative’s Warrant nor any of the Ordinary Shares issued upon exercise of the Representative’s Warrant may be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities by any person, for a period of 180 days beginning on immediately following the date of commencement effectiveness of sales of this Offering the Registration Statement pursuant to which the Representative’s Warrant is being issued, subject to certain exceptions permitted by FINRA Rule 5110(e)(2)exceptions.